{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:10:05Z","timestamp":1789420205639,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40259-022-00517-x","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:03:07Z","timestamp":1647943387000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Enhancing the Response Rate to Recombinant Uricases in Patients with Gout"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-1202","authenticated-orcid":false,"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-4844","authenticated-orcid":false,"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-241X","authenticated-orcid":false,"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"issue":"10","key":"517_CR1","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1073\/pnas.1320393111","volume":"111","author":"JT Kratzer","year":"2014","unstructured":"Kratzer JT, Lanaspa MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014;111(10):3763\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"517_CR2","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1096\/fasebj.2.15.3192041","volume":"2","author":"A Varela-Echavarr\u00eda","year":"1988","unstructured":"Varela-Echavarr\u00eda A, de Oca-Luna RM, Barrera-Salda\u00f1a HA. Uricase protein sequences: conserved during vertebrate evolution but absent in humans. FASEB J. 1988;2(15):3092\u20136.","journal-title":"FASEB J"},{"issue":"Suppl 1","key":"517_CR3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar1909","volume":"8","author":"R Terkeltaub","year":"2006","unstructured":"Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006;8(Suppl 1):S4.","journal-title":"Arthritis Res Ther"},{"key":"517_CR4","unstructured":"Terkeltaub R. Gout: diagnosis and management of gouty arthritis and hyperuricemia, 3rd edn. Professional Communications, Inc; 2013."},{"key":"517_CR5","unstructured":"Edwards NL. Gout. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic diseases. New York: Springer New York; 2008. p. 241\u201362."},{"issue":"10","key":"517_CR6","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.3390\/jcm9103204","volume":"9","author":"P Khanna","year":"2020","unstructured":"Khanna P, Johnson RJ, Marder B, LaMoreaux B, Kumar A. Systemic urate deposition: an unrecognized complication of gout? J Clin Med. 2020;9(10):3204.","journal-title":"J Clin Med"},{"issue":"3","key":"517_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jbspin.2012.01.004","volume":"79","author":"RP Garay","year":"2012","unstructured":"Garay RP, El-Gewely MR, Labaune JP, Richette P. Therapeutic perspectives on uricases for gout. Jt Bone Spine. 2012;79(3):237\u201342.","journal-title":"Jt Bone Spine"},{"key":"517_CR8","unstructured":"KRYSTEXXA (pegloticase injection) [package insert]. Horizon Therapeutics Ireland DAC; 2020."},{"issue":"7","key":"517_CR9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711\u201320.","journal-title":"JAMA"},{"issue":"2","key":"517_CR10","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"517_CR11","first-page":"1942","volume":"29","author":"JS Bomalaski","year":"2002","unstructured":"Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002;29(9):1942\u20139.","journal-title":"J Rheumatol"},{"issue":"10","key":"517_CR12","first-page":"2093","volume":"34","author":"P Richette","year":"2007","unstructured":"Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34(10):2093\u20138.","journal-title":"J Rheumatol"},{"issue":"7","key":"517_CR13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D\u2019Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"517_CR14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","volume":"11","author":"S Ben-Horin","year":"2013","unstructured":"Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"517_CR15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001047","volume":"6","author":"E Ducourau","year":"2020","unstructured":"Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020;6(1): e001047.","journal-title":"RMD Open"},{"issue":"11","key":"517_CR16","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"517_CR17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","volume":"74","author":"E Lie","year":"2015","unstructured":"Lie E, Kristensen LE, Forsblad-d\u2019Elia H, Zverkova-Sandstrom T, Askling J, Jacobsson LT, et al. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF-inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis. 2015;74(6):970\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"517_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MIB.0000456699.04243.9e","volume":"20","author":"S O'Meara","year":"2014","unstructured":"O\u2019Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(1):1\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"517_CR19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","volume":"45","author":"AS Strik","year":"2017","unstructured":"Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D\u2019Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"517_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299\u2013316.","journal-title":"BioDrugs"},{"issue":"9","key":"517_CR21","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552\u201363.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"517_CR22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","volume":"48","author":"JK Botson","year":"2021","unstructured":"Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J Rheumatol. 2021;48(5):767\u201374.","journal-title":"J Rheumatol"},{"issue":"2","key":"517_CR23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, Botson JK, Masri KR, Padnick-Silver L, LaMoreaux B, Albert JA, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51(2):347\u201352.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"517_CR24","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","volume":"73","author":"PP Khanna","year":"2021","unstructured":"Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2021;73(8):1523\u201332.","journal-title":"Arthritis Rheum"},{"key":"517_CR25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","volume":"11","author":"TK Kishimoto","year":"2020","unstructured":"Kishimoto TK. Development of ImmTOR\u2122 tolerogenic nanoparticles for the mitigation of anti-drug antibodies. Front Immunol. 2020;11:969.","journal-title":"Front Immunol"},{"key":"517_CR26","first-page":"367","volume":"76","author":"E Sands","year":"2017","unstructured":"Sands E, Kivitz AJ, DeHaan W, Johnston L, Kishimoto TK. SEL-212: enhanced serum uric acid control in hyperuricemic patients through selective mitigation of anti-drug antibodies against pegsiticase [abstract]. Ann Rheum Dis. 2017;76:367.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"517_CR27","first-page":"2487","volume":"70","author":"E Sands","year":"2018","unstructured":"Sands E, Kivitz AJ, DeHaan W, Johnston L, Kishimoto TK. Update of SEL-212 phase 2 clinical data in symptomatic gout patients: Svp-rapamycin combined with pegadricase mitigates immunogenicity and enables sustained reduction of serum uric acid levels, low rate of gout flares and monthly dosing [abstract]. Arthritis Rheum. 2018;70(Suppl 10):2487.","journal-title":"Arthritis Rheum."},{"issue":"Suppl 1","key":"517_CR28","first-page":"847","volume":"80","author":"Y Song","year":"2021","unstructured":"Song Y, Xin Y, Weinblatt ME, Chamberlain J, Obermeyer K, Zhao L, et al. POS1136 Pharmacokinetics of pegloticase and methotrexate polyglutamate(s) in patients with uncontrolled gout receiving pegloticase and co-treatment of methotrexate. Ann Rheum Dis. 2021;80(Suppl 1):847\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3254","key":"517_CR29","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1126\/science.125.3254.937","volume":"125","author":"M London","year":"1957","unstructured":"London M, Hudson PB. Uricolytic activity of purified uricase in two human beings. Science. 1957;125(3254):937\u20138.","journal-title":"Science"},{"issue":"2","key":"517_CR30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","volume":"38","author":"KC Allen","year":"2015","unstructured":"Allen KC, Champlain AH, Cotliar JA, Belknap SM, West DP, Mehta J, et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 2015;38(2):183\u20137.","journal-title":"Drug Saf"},{"issue":"2","key":"517_CR31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","volume":"6","author":"RT Keenan","year":"2019","unstructured":"Keenan RT, Baraf HSB, LaMoreaux B. Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase. Rheumatol Ther. 2019;6(2):299\u2013304.","journal-title":"Rheumatol Ther."},{"issue":"2","key":"517_CR32","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","volume":"105","author":"PL Turecek","year":"2016","unstructured":"Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105(2):460\u201375.","journal-title":"J Pharm Sci"},{"key":"517_CR33","unstructured":"ELITEK (rasburicase injection) [package insert]. Bridgewater (NJ): Sanofi-Aventis U.S. LLC; 2019."},{"issue":"10","key":"517_CR34","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","volume":"15","author":"CH Pui","year":"2001","unstructured":"Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15(10):1505\u20139.","journal-title":"Leukemia"},{"issue":"3","key":"517_CR35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","volume":"19","author":"CH Pui","year":"2001","unstructured":"Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19(3):697\u2013704.","journal-title":"J Clin Oncol"},{"issue":"6","key":"517_CR36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"517_CR37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","volume":"56","author":"JS Sundy","year":"2007","unstructured":"Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56(3):1021\u20138.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"517_CR38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","volume":"20","author":"HS Baraf","year":"2014","unstructured":"Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014;20(8):427\u201332.","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"517_CR39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","volume":"11","author":"TK Kishimoto","year":"2016","unstructured":"Kishimoto TK, Ferrari JD, LaMothe RA, Kolte PN, Griset AP, O\u2019Neil C, et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat Nanotechnol. 2016;11(10):890\u20139.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"517_CR40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145\u201354.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"517_CR41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","volume":"46","author":"AA Berhanu","year":"2017","unstructured":"Berhanu AA, Krasnokutsky S, Keenan RT, Pillinger MH. Pegloticase failure and a possible solution: immunosuppression to prevent intolerance and inefficacy in patients with gout. Semin Arthritis Rheum. 2017;46(6):754\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"517_CR42","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.transproceed.2018.03.010","volume":"50","author":"B Freyne","year":"2018","unstructured":"Freyne B. A case report of immunosuppressant medication-associated polyarticular tophaceous gout successfully treated using the polyethylene glycol-conjugated uricase enzyme pegloticase. Transplant Proc. 2018;50(10):4099\u2013101.","journal-title":"Transplant Proc"},{"key":"517_CR43","first-page":"238","volume":"14","author":"MY Bessen","year":"2019","unstructured":"Bessen MY, Bessen SY, Yung CM. Concomitant immunosuppressant use with pegloticase in patients with tophaceous gout\u2014a case series. Int J Clin Rheumatol. 2019;14:238\u201345.","journal-title":"Int J Clin Rheumatol"},{"issue":"1","key":"517_CR44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semarthrit.2018.11.006","volume":"49","author":"SY Bessen","year":"2019","unstructured":"Bessen SY, Bessen MY, Yung CM. Recapture and improved outcome of pegloticase response with methotrexate-a report of two cases and review of the literature. Semin Arthritis Rheum. 2019;49(1):56\u201361.","journal-title":"Semin Arthritis Rheum"},{"key":"517_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001639","author":"JK Botson","year":"2020","unstructured":"Botson JK, Peterson J. Pretreatment and coadministration with methotrexate improved durability of pegloticase response: an observational, proof-of-concept case series. J Clin Rheumatol. 2020. https:\/\/doi.org\/10.1097\/RHU.0000000000001639.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"517_CR46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40744-020-00222-7","volume":"7","author":"JA Albert","year":"2020","unstructured":"Albert JA, Hosey T, LaMoreaux B. Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co-treated with methotrexate: a retrospective study. Rheumatol Ther. 2020;7(3):639\u201348.","journal-title":"Rheumatol Ther."},{"key":"517_CR47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2019-215731","volume":"79","author":"B LaMoreaux","year":"2020","unstructured":"LaMoreaux B, Francis-Sedlak M, Svensson K, Holt R. Immunomodulation co-therapy with pegloticase: database trends 2014\u20132019 [abstract]. Ann Rheum Dis. 2020;79:108.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"517_CR48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/annrheumdis-2020-eular.3891","volume":"79","author":"K Masri","year":"2020","unstructured":"Masri K, Winterling K, Lamoreaux B. Leflunomide co-therapy with pegloticase in uncontrolled gout [abstract]. Ann Rheum Dis. 2020;79(Suppl 1):454.","journal-title":"Ann Rheum Dis"},{"key":"517_CR49","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/annrheumdis-2020-eular.4642","volume":"79","author":"H Rainey","year":"2020","unstructured":"Rainey H, Baraf HS, Yeo AE, Lipsky PE. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout [abstract]. Ann Rheum Dis. 2020;79:438.","journal-title":"Ann Rheum Dis"},{"key":"517_CR50","unstructured":"Horizon Therapeutics. MIRROR randomized controlled trial meets primary endpoint and shows 71% of patients achieved a complete response rate using KRYSTEXXA\u00ae (pegloticase injection) with methotrexate [Internet]. Dublin, Ireland; 2021 Oct 25 [cited 2021 Dec 13]. https:\/\/ir.horizontherapeutics.com\/news-releases\/news-release-details\/mirror-randomized-controlled-trial-meets-primary-endpoint-and. Accessed 1\u00a0Dec 2021."},{"issue":"10","key":"517_CR51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/01.tp.0000188722.84775.af","volume":"80","author":"KC Abbott","year":"2005","unstructured":"Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383\u201391.","journal-title":"Transplantation"},{"key":"517_CR52","unstructured":"Abdellatif A, Zhao L, Peloso P, Cherny K, Marder B, Scandling J, et al. A multicenter, open-label, efficacy and safety study of pegloticase in patients with uncontrolled gout who have undergone kidney transplantation: early data report [abstract]. Arthritis Rheum. 2020;72(Suppl 10)."},{"key":"517_CR53","unstructured":"Abdellatif A, Zhao L, Peloso PM, Charney K, Marder B, Scandling J, et al. Pegloticase treatment for uncontrolled gout in kidney transplanted patients: results of an on-going multicenter, open-label, efficacy and safety study [abstract]. Arthritis Rheum. 2021;73(Suppl 9)."},{"key":"517_CR54","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2021-eular.97","volume":"80","author":"A Abdellatif","year":"2021","unstructured":"Abdellatif A, Zhao L, Peloso P, Cherny K, Marder B, Scandling J, et al. Preliminary findings of the PROTECT clinical trial: pegloticase efficacy and safety in kidney transplant recipients [abstract]. Ann Rheum Dis. 2021;80:840.","journal-title":"Ann Rheum Dis"},{"key":"517_CR55","doi-asserted-by":"publisher","DOI":"10.1042\/ETLS20210127","author":"C Brunn","year":"2021","unstructured":"Brunn C, Kishimoto TK. ImmTOR\u2122 to amplify the efficacy and reduce immunogenicity of biologics. Emerg Top Life Sci. 2021. https:\/\/doi.org\/10.1042\/ETLS20210127.","journal-title":"Emerg Top Life Sci."},{"issue":"2","key":"517_CR56","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","volume":"112","author":"RA Maldonado","year":"2015","unstructured":"Maldonado RA, LaMothe RA, Ferrari JD, Zhang A-H, Rossi RJ, Kolte PN, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A. 2015;112(2):E156.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"517_CR57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hon.2700","volume":"38","author":"R Moia","year":"2020","unstructured":"Moia R, Boggio E, Gigliotti L, Cris\u00e0 E, De Paoli L, Margiotta Casaluci G, et al. Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. Hematol Oncol. 2020;38(2):204\u20136.","journal-title":"Hematol Oncol"},{"issue":"2","key":"517_CR58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O\u2019Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155\u201363.","journal-title":"Am J Med"},{"issue":"3","key":"517_CR59","first-page":"199","volume":"68","author":"MH Pillinger","year":"2010","unstructured":"Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis. 2010;68(3):199\u2013203.","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"7","key":"517_CR60","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125(7):679\u201387.","journal-title":"Am J Med"},{"issue":"4","key":"517_CR61","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.","journal-title":"Cells"},{"key":"517_CR62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-0500-7-54","volume":"7","author":"RA Yood","year":"2014","unstructured":"Yood RA, Ottery FD, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes. 2014;7:54.","journal-title":"BMC Res Notes"},{"key":"517_CR63","unstructured":"Methotrexate injection [package insert]. Lake Forest (IL): Hospira Inc.; 2021."},{"issue":"11","key":"517_CR64","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1432-2277.2009.00927.x","volume":"22","author":"D Weiskopf","year":"2009","unstructured":"Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22(11):1041\u201350.","journal-title":"Transpl Int"},{"key":"517_CR65","unstructured":"PubChem Compound Summary for CID 86278331, Pegadricase. [Internet]. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Pegadricase. Accessed 11 Nov 2021."},{"issue":"1","key":"517_CR66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri1256","volume":"4","author":"H Hackstein","year":"2004","unstructured":"Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol. 2004;4(1):24\u201334.","journal-title":"Nat Rev Immunol"},{"key":"517_CR67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/B978-0-12-380995-7.00004-5","volume":"108","author":"RA Maldonado","year":"2010","unstructured":"Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111\u201365.","journal-title":"Adv Immunol"},{"issue":"1","key":"517_CR68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","volume":"34","author":"V Strand","year":"2020","unstructured":"Strand V, Goncalves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34(1):27\u201337.","journal-title":"BioDrugs"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00517-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T11:38:38Z","timestamp":1649245118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00517-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00517-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"25 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Manuscript development was supported by Horizon Therapeutics plc (Deerfield, IL, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NS has received grants from Amgen and is a consultant to and advisory board member for Horizon Therapeutics, Alnylam Pharmaceuticals, and JW Pharmaceutical Corporation. BL and LP-S are employees of and stockholders in Horizon Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This review did not involve the collection or analysis of new data and only examined data already published in the literature.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This review only contains aggregate findings from published studies and does not contain individual patient data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}